Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia

Ventilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD were evaluated during 9 -- 42 days postpartum (mean = 31 days) and were divided into two groups: Group I - 14 newborns that did not receive dexamethasone, and Group II - 12 newborns that received dexamethasone at 14 --21 days of life. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered. RESULTS: There were no statistically significant differences in the mean length of mechanical ventilation (Group I - 37 days, Group II - 35 days); oxygen supplementation (Group I - 16 days, Group II - 29 days); hospital stay (Group I - 72 days, Group II - 113 days); mortality (Group I - 35.7%, Group II - 41.6%). At birth, Group II was lighter (BW: Group I - 1154 grams ± 302, Group II - 791 grams ± 165; p < 0.05) and smaller (height: Group I - 37.22 cm ± 3.3, Group II - 33.5 ± 2.4; p< 0.05) than Group I. At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements. CONCLUSIONS: The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its suspension, a recovery seems to occur, suggesting that its influence could be transitory.

Saved in:
Bibliographic Details
Main Authors: Mataloun,Marta M. G. B., Gibelli,Maria Augusta C., Kato,Ana V., Vaz,Flávio Adolfo Costa, Leone,Cléa Rodrigues
Format: Digital revista
Language:English
Published: Faculdade de Medicina / Universidade de São Paulo - FM/USP 1999
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87811999000600002
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0041-87811999000600002
record_format ojs
spelling oai:scielo:S0041-878119990006000022000-07-20Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasiaMataloun,Marta M. G. B.Gibelli,Maria Augusta C.Kato,Ana V.Vaz,Flávio Adolfo CostaLeone,Cléa Rodrigues Dexamethasone therapy Bronchopulmonary dysplasia Ventilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD were evaluated during 9 -- 42 days postpartum (mean = 31 days) and were divided into two groups: Group I - 14 newborns that did not receive dexamethasone, and Group II - 12 newborns that received dexamethasone at 14 --21 days of life. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered. RESULTS: There were no statistically significant differences in the mean length of mechanical ventilation (Group I - 37 days, Group II - 35 days); oxygen supplementation (Group I - 16 days, Group II - 29 days); hospital stay (Group I - 72 days, Group II - 113 days); mortality (Group I - 35.7%, Group II - 41.6%). At birth, Group II was lighter (BW: Group I - 1154 grams ± 302, Group II - 791 grams ± 165; p < 0.05) and smaller (height: Group I - 37.22 cm ± 3.3, Group II - 33.5 ± 2.4; p< 0.05) than Group I. At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements. CONCLUSIONS: The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its suspension, a recovery seems to occur, suggesting that its influence could be transitory.info:eu-repo/semantics/openAccessFaculdade de Medicina / Universidade de São Paulo - FM/USPRevista do Hospital das Clínicas v.54 n.6 19991999-12-01info:eu-repo/semantics/articletext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87811999000600002en10.1590/S0041-87811999000600002
institution SCIELO
collection OJS
country Brasil
countrycode BR
component Revista
access En linea
databasecode rev-scielo-br
tag revista
region America del Sur
libraryname SciELO
language English
format Digital
author Mataloun,Marta M. G. B.
Gibelli,Maria Augusta C.
Kato,Ana V.
Vaz,Flávio Adolfo Costa
Leone,Cléa Rodrigues
spellingShingle Mataloun,Marta M. G. B.
Gibelli,Maria Augusta C.
Kato,Ana V.
Vaz,Flávio Adolfo Costa
Leone,Cléa Rodrigues
Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
author_facet Mataloun,Marta M. G. B.
Gibelli,Maria Augusta C.
Kato,Ana V.
Vaz,Flávio Adolfo Costa
Leone,Cléa Rodrigues
author_sort Mataloun,Marta M. G. B.
title Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_short Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_full Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_fullStr Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_full_unstemmed Use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
title_sort use of corticosteroids and the outcome of infants with bronchopulmonary dysplasia
description Ventilator-dependent premature infants are often treated with dexamethasone. Several trials showed that steroids while improve pulmonary compliance and facilitate extubation, some treated infants may have adverse effects, such as alterations of growth curves. We conducted this retrospective study to evaluate the effects of steroids on mechanical ventilation, oxygen therapy, hospital length stay and mortality, in ventilator-dependent infants with bronchopulmonary dysplasia (BPD) (defined as the need of oxygen supplementation at 28 days of life). Twenty-six newborns with BPD were evaluated during 9 -- 42 days postpartum (mean = 31 days) and were divided into two groups: Group I - 14 newborns that did not receive dexamethasone, and Group II - 12 newborns that received dexamethasone at 14 --21 days of life. Dexamethasone was given at a dose of 0.25 mg per kilogram of body weight twice daily intravenously for 3 days, after which the dose was tapered. RESULTS: There were no statistically significant differences in the mean length of mechanical ventilation (Group I - 37 days, Group II - 35 days); oxygen supplementation (Group I - 16 days, Group II - 29 days); hospital stay (Group I - 72 days, Group II - 113 days); mortality (Group I - 35.7%, Group II - 41.6%). At birth, Group II was lighter (BW: Group I - 1154 grams ± 302, Group II - 791 grams ± 165; p < 0.05) and smaller (height: Group I - 37.22 cm ± 3.3, Group II - 33.5 ± 2.4; p< 0.05) than Group I. At 40 weeks, there were no statistically significant differences between groups in relation to anthropometric measurements. CONCLUSIONS: The use of corticosteroids in bronchopulmonary dysplasic infants may influence the somatic growth during its use. However, after its suspension, a recovery seems to occur, suggesting that its influence could be transitory.
publisher Faculdade de Medicina / Universidade de São Paulo - FM/USP
publishDate 1999
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0041-87811999000600002
work_keys_str_mv AT matalounmartamgb useofcorticosteroidsandtheoutcomeofinfantswithbronchopulmonarydysplasia
AT gibellimariaaugustac useofcorticosteroidsandtheoutcomeofinfantswithbronchopulmonarydysplasia
AT katoanav useofcorticosteroidsandtheoutcomeofinfantswithbronchopulmonarydysplasia
AT vazflavioadolfocosta useofcorticosteroidsandtheoutcomeofinfantswithbronchopulmonarydysplasia
AT leoneclearodrigues useofcorticosteroidsandtheoutcomeofinfantswithbronchopulmonarydysplasia
_version_ 1756380781254541312